Dachaigh › Leukemia Myelomonocytic Cronach › Texas
Sgrùdaidhean clionaigeach Leukemia Myelomonocytic Cronach ann an Texas
Tha 18 sgrùdaidhean airson Leukemia Myelomonocytic Cronach a’ lorg phàirtichean aig làraichean ann an Texas.
Bailtean ann an Texas
Teacsa sgrùdaidh oifigeil (Beurla)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
A’ fastadhÌre 2Fàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT03383575Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
- MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT07033598Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- AIR Care, Dallas
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 12 Lùna 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 2/3Fàilte do shaor-thoilich fhallain
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 12 gu 80 · Gach gnè · Air ùrachadh 7 Lùna 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 15 gu 80 · Gach gnè · Air ùrachadh 30 Iuch 2026 · NCT02727803Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Iuch 2026 · NCT07128381A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Cèit 2026 · NCT04239157CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Cèit 2026 · NCT03896269A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Gibl 2026 · NCT04256317Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT04140487A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
A’ fastadhÌre 2
Aoisean 18 gu 66 · Gach gnè · Air ùrachadh 17 Màrt 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 16 Màrt 2026 · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Gearr 2026 · NCT06950034Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- MD Anderson Cancer Center, Huston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Lùna 2025 · NCT03850574Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.